用抗素缺乏疗法治疗患者的认知功能障碍:一项多模式功能成像研究来评估神经炎症
Azeem Saleem1,2, Syed Imran Ali Shah3,4, Stephen A Mangar5
1Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
Prostate cancer
|October 27, 2023
概括
抗雄激素剥夺疗法可能会导致认知问题. 用PET-TSPO测量的神经炎症在前列腺癌患者与认知障碍或没有认知障碍之间没有差异,但与大脑活动相关.
科学领域:
- 神经科学是一个神经科学.
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
背景情况:
- 使用雄激素剥夺疗法 (ADT) 治疗前列腺癌与认知障碍 (CI) 有关.
- 神经炎症是认知衰退的一个已知的因素,在痴呆症和阿尔茨海默病中见到.
- 这项研究探讨了神经炎症在ADT相关CI中的潜在作用.
研究的目的:
- 调查神经炎症是否会导致前列腺癌患者接受ADT的认知障碍.
- 为了比较ADT出现的CI患者和正常认知 (NC) 患者之间的神经炎症水平.
主要方法:
- 接受ADT治疗至少三个月的前列腺癌患者通过自我报告来评估CI或NC.
- 通过使用转位蛋白 (TSPO) 放射性连接体[11C]-PBR28.0的正子发射断层扫描 (PET) 来测量神经炎症.
- 分析了PET吸收 (SUVR) 和功能性MRI (BOLD-fMRI) 选择反应时间任务 (CRT) 激活.
主要成果:
- 报告CI (rCI) 和报告NC (rNC) 的患者之间没有发现[11C]-PBR28摄入 (神经炎症) 的显著差异.
- 在CRT任务期间的大脑激活模式在rCI和rNC组之间没有差异.
- 在海马体,杏仁体和中间皮层中,TSPO信号和BOLD-fMRI激活之间观察到强烈的相关性,无论认知状态如何.
结论:
- 通过PET-TSPO评估的神经炎症,没有区分具有或没有认知障碍的ADT患者.
- TSPO吸收和大脑激活之间的相关性可能表明ADT的炎症影响影响记忆相关区域的突触功能.
- 需要使用这些成像技术进行进一步的研究,以充分理解与ADT相关的认知障碍.
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...


![Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58641.jpg&w=3840&q=50)